Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
We discuss results of ORIGIN, a multicenter parallel groups study for efficiency assessment of insulin glargin against polyunsaturatedomega-3 fatty acids or placebo regarding cardiovascular and/or mortality risk reduction in patients with impaired fasting glycemia,impaired glucose tolerance or type...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2012-09-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/6092 |
| _version_ | 1797255300715118592 |
|---|---|
| author | Elena Valer'evna Biryukova Alexander Sergeevich Ametov Mikhail Borisovich Antsiferov Alsu Gafurovna Zalevskaya Galina Afanas'evna Mel'nichenko Ashot Musaelovich Mkrtumyan Marina Vladimirovna Shestakova |
| author_facet | Elena Valer'evna Biryukova Alexander Sergeevich Ametov Mikhail Borisovich Antsiferov Alsu Gafurovna Zalevskaya Galina Afanas'evna Mel'nichenko Ashot Musaelovich Mkrtumyan Marina Vladimirovna Shestakova |
| author_sort | Elena Valer'evna Biryukova |
| collection | DOAJ |
| description | We discuss results of ORIGIN, a multicenter parallel groups study for efficiency assessment of insulin glargin against polyunsaturatedomega-3 fatty acids or placebo regarding cardiovascular and/or mortality risk reduction in patients with impaired fasting glycemia,impaired glucose tolerance or type 2 diabetes mellitus (T2DM) on its early stage and high risk for cardiovascular events. 12 537 patientstook part in this study; 6 264 were randomized in insulin glargin group, where dosage was adjusted for complete compensationof fasting glycemia (5.3 mmol/l was set as a therapeutic goal). After treatment with glargin therapeutic goal was achieved and furthermaintained for 6.2 years of follow-up. Compensation of fasting glycemia did not affect the outcome of cardiovascular diseases in patientswith early stages of dysglycemia according to primary endpoints. It was not associated with increase in general morbidity and inrisk of hypoglycemic events. Treatment with insulin glargin delayed progression from prediabetes to clinical onset for 28% (OR 0.72,CI 95% 0.58-0.91; p = 0,006), while lowering incidence of DM. Longtime treatment with insulin glargin does not increase incidenceof malignant tumors of different localization, including patients with prediabetes. Due to results of ORIGIN, insulin glargin (Lantus?)has become the most studied human insulin analogue to date. |
| first_indexed | 2024-03-08T15:21:39Z |
| format | Article |
| id | doaj.art-b7e6d26cdbee4110988b38b6e29a334f |
| institution | Directory Open Access Journal |
| issn | 2072-0351 2072-0378 |
| language | English |
| last_indexed | 2024-04-24T22:03:40Z |
| publishDate | 2012-09-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj.art-b7e6d26cdbee4110988b38b6e29a334f2024-03-20T11:47:57ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782012-09-011539210010.14341/2072-0351-60926050Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN studyElena Valer'evna Biryukova0Alexander Sergeevich Ametov1Mikhail Borisovich Antsiferov2Alsu Gafurovna Zalevskaya3Galina Afanas'evna Mel'nichenko4Ashot Musaelovich Mkrtumyan5Marina Vladimirovna Shestakova6Moscow State University of Medicine and Dentistry, Moscow, Russian FederationRussian Medical Academy of Postgraduate Education, Russian FederationMoscow Endocrinology Health Centre, MoscowSt. Petersburg Pavlov State Medical University, St. PetersburgEndocrinology Research Centre, MoscowMoscow State University of Medicine and Dentistry, Moscow, Russian FederationEndocrinology Research Centre, MoscowWe discuss results of ORIGIN, a multicenter parallel groups study for efficiency assessment of insulin glargin against polyunsaturatedomega-3 fatty acids or placebo regarding cardiovascular and/or mortality risk reduction in patients with impaired fasting glycemia,impaired glucose tolerance or type 2 diabetes mellitus (T2DM) on its early stage and high risk for cardiovascular events. 12 537 patientstook part in this study; 6 264 were randomized in insulin glargin group, where dosage was adjusted for complete compensationof fasting glycemia (5.3 mmol/l was set as a therapeutic goal). After treatment with glargin therapeutic goal was achieved and furthermaintained for 6.2 years of follow-up. Compensation of fasting glycemia did not affect the outcome of cardiovascular diseases in patientswith early stages of dysglycemia according to primary endpoints. It was not associated with increase in general morbidity and inrisk of hypoglycemic events. Treatment with insulin glargin delayed progression from prediabetes to clinical onset for 28% (OR 0.72,CI 95% 0.58-0.91; p = 0,006), while lowering incidence of DM. Longtime treatment with insulin glargin does not increase incidenceof malignant tumors of different localization, including patients with prediabetes. Due to results of ORIGIN, insulin glargin (Lantus?)has become the most studied human insulin analogue to date.https://www.dia-endojournals.ru/jour/article/view/6092prediabetesdiabetes mellitushypoglycemiaoncologyonsulin glarginorigin study |
| spellingShingle | Elena Valer'evna Biryukova Alexander Sergeevich Ametov Mikhail Borisovich Antsiferov Alsu Gafurovna Zalevskaya Galina Afanas'evna Mel'nichenko Ashot Musaelovich Mkrtumyan Marina Vladimirovna Shestakova Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study Сахарный диабет prediabetes diabetes mellitus hypoglycemia oncology onsulin glargin origin study |
| title | Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study |
| title_full | Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study |
| title_fullStr | Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study |
| title_full_unstemmed | Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study |
| title_short | Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study |
| title_sort | metabolic and cardiovascular effects of early insulin glargin prescription based on data from origin study |
| topic | prediabetes diabetes mellitus hypoglycemia oncology onsulin glargin origin study |
| url | https://www.dia-endojournals.ru/jour/article/view/6092 |
| work_keys_str_mv | AT elenavalerevnabiryukova metabolicandcardiovasculareffectsofearlyinsulinglarginprescriptionbasedondatafromoriginstudy AT alexandersergeevichametov metabolicandcardiovasculareffectsofearlyinsulinglarginprescriptionbasedondatafromoriginstudy AT mikhailborisovichantsiferov metabolicandcardiovasculareffectsofearlyinsulinglarginprescriptionbasedondatafromoriginstudy AT alsugafurovnazalevskaya metabolicandcardiovasculareffectsofearlyinsulinglarginprescriptionbasedondatafromoriginstudy AT galinaafanasevnamelnichenko metabolicandcardiovasculareffectsofearlyinsulinglarginprescriptionbasedondatafromoriginstudy AT ashotmusaelovichmkrtumyan metabolicandcardiovasculareffectsofearlyinsulinglarginprescriptionbasedondatafromoriginstudy AT marinavladimirovnashestakova metabolicandcardiovasculareffectsofearlyinsulinglarginprescriptionbasedondatafromoriginstudy |